Sam Joseph
Endocrinology · Feasterville Trevose, PANPI 1659833424
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,200 and has fallen 80.3% since, to $236 in 2025. Among endocrinology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$571
- Novo Nordisk$478
- AstraZeneca$437
- Sanofi-aventis U.S. LLC$281
- Lilly USA, LLC$165
- Radius Health, Inc.$127
- plus $734 from 15 others
What the payments were for
- Food & beverage$2,69697%
- Education$973%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 9 | $571 |
| Novo Nordisk | 16 | $478 |
| AstraZeneca(2 entities) | 7 | $437 |
| Sanofi-aventis U.S. LLC | 5 | $281 |
| Lilly USA, LLC | 5 | $165 |
| Radius Health, Inc. | 6 | $127 |
| Amgen | 7 | $122 |
| AbbVie | 6 | $99 |
| Aurinia Pharma U.S., Inc. | 4 | $92 |
| Averitas Pharma Inc. | 3 | $76 |
| UCB, Inc. | 3 | $56 |
| Ascensia Diabetes Care US Inc. | 2 | $56 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Boehringer Ingelheim | 3 | $44 |
| Antares Pharma, Inc. | 2 | $38 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Halozyme Inc | 1 | $15 |
| Bayer | 1 | $14 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$249
- FARXIGA$246
- MINIMED 780G$201
- MOUNJARO$121
- MINIMED 770G$115
How this compares
$2,793 in reported general payments places this provider in the 95th percentile of 22 endocrinology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $192,122 |
| JardianceEmpagliflozin | 83 | $108,547 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $43,454 |
| MounjaroTirzepatide | 25 | $40,341 |
| FarxigaDapagliflozin Propanediol | 29 | $34,365 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $28,831 |
| TrulicityDulaglutide | 21 | $28,691 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $25,563 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $16,933 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $11,552 |
| Humalog Kwikpen U-100Insulin Lispro | 27 | $10,778 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $9,131 |
| Novolog FlexpenInsulin Aspart | 26 | $8,186 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 57 | $6,478 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $5,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $478 | $194,809118 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $44 | $137,378101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $165 | $69,03246 claims |
| AstraZenecaFarxiga | $437 | $34,36529 claims |
| AbbVieSynthroid | $99 | $1,20721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 22 endocrinology providers in Pennsylvania.
Other endocrinology in Feasterville Trevose
- Mohammad ArastuBethlehem$2K
- Edward RubyDarby$2K
- Diana PinkhasovaPittsburgh$2K
- Javier Ocampo MascaroPhiladelphia$671
- Maja Stefanovic-RacicPittsburgh$491
- Steven HodakPittsburgh$190
- Susan GreenspanPittsburgh$162
- Julia KharlipPhiladelphia$0
- Daniel RubinPhiladelphia$0
- Hamdee AttallahPhiladelphia$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.